Literature DB >> 11401993

Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

B M Price1, A L Liner, S Park, S H Leppla, A Mateczun, D R Galloway.   

Abstract

The ability of genetic vaccination to protect against a lethal challenge of anthrax toxin was evaluated. BALB/c mice were immunized via gene gun inoculation with eucaryotic expression vector plasmids encoding either a fragment of the protective antigen (PA) or a fragment of lethal factor (LF). Plasmid pCLF4 contains the N-terminal region (amino acids [aa] 10 to 254) of Bacillus anthracis LF cloned into the pCI expression plasmid. Plasmid pCPA contains a biologically active portion (aa 175 to 764) of B. anthracis PA cloned into the pCI expression vector. One-micrometer-diameter gold particles were coated with plasmid pCLF4 or pCPA or a 1:1 mixture of both and injected into mice via gene gun (1 microg of plasmid DNA/injection) three times at 2-week intervals. Sera were collected and analyzed for antibody titer as well as antibody isotype. Significantly, titers of antibody to both PA and LF from mice immunized with the combination of pCPA and pCLF4 were four to five times greater than titers from mice immunized with either gene alone. Two weeks following the third and final plasmid DNA boost, all mice were challenged with 5 50% lethal doses of lethal toxin (PA plus LF) injected intravenously into the tail vein. All mice immunized with pCLF4, pCPA, or the combination of both survived the challenge, whereas all unimmunized mice did not survive. These results demonstrate that DNA-based immunization alone can provide protection against a lethal toxin challenge and that DNA immunization against the LF antigen alone provides complete protection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401993      PMCID: PMC98526          DOI: 10.1128/IAI.69.7.4509-4515.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  32 in total

Review 1.  DNA vaccines -- a modern gimmick or a boon to vaccinology?

Authors:  E Manickan; K L Karem; B T Rouse
Journal:  Crit Rev Immunol       Date:  1997       Impact factor: 2.214

2.  Crystal structure of the anthrax toxin protective antigen.

Authors:  C Petosa; R J Collier; K R Klimpel; S H Leppla; R C Liddington
Journal:  Nature       Date:  1997-02-27       Impact factor: 49.962

3.  Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization.

Authors:  D M Feltquate; S Heaney; R G Webster; H L Robinson
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

4.  Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice.

Authors:  D Haddad; S Liljeqvist; S Ståhl; I Andersson; P Perlmann; K Berzins; N Ahlborg
Journal:  FEMS Immunol Med Microbiol       Date:  1997-07

Review 5.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha.

Authors:  R Pellizzari; C Guidi-Rontani; G Vitale; M Mock; C Montecucco
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

7.  Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs.

Authors:  B Ivins; P Fellows; L Pitt; J Estep; J Farchaus; A Friedlander; P Gibbs
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

8.  Protective immunity induced by Bacillus anthracis toxin-deficient strains.

Authors:  C Pezard; M Weber; J C Sirard; P Berche; M Mock
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.

Authors:  K R Klimpel; N Arora; S H Leppla
Journal:  Mol Microbiol       Date:  1994-09       Impact factor: 3.501

10.  Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A.

Authors:  K S Denis-Mize; B M Price; N R Baker; D R Galloway
Journal:  FEMS Immunol Med Microbiol       Date:  2000-02
View more
  47 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Development of an improved vaccine for anthrax.

Authors:  Stephen H Leppla; John B Robbins; Rachel Schneerson; Joseph Shiloach
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

4.  Pathophysiological manifestations in mice exposed to anthrax lethal toxin.

Authors:  Nathan C Culley; David M Pinson; Anuradha Chakrabarty; Matthew S Mayo; Steven M LeVine
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.

Authors:  Eric K Dumas; Lori Garman; Hannah Cuthbertson; Sue Charlton; Bassam Hallis; Renata J M Engler; Shyamal Choudhari; William D Picking; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2017-05-11       Impact factor: 3.641

Review 7.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

8.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

9.  Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.

Authors:  Sha Cao; Aizhen Guo; Ziduo Liu; Yadi Tan; Gaobing Wu; Chengcai Zhang; Yaxing Zhao; Huanchun Chen
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

Review 10.  Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.

Authors:  Holger Barth; Klaus Aktories; Michel R Popoff; Bradley G Stiles
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.